Health Canada has authorised CSL Behring’s Hemgenix, further expanding the reach of the haemophilia B gene therapy after approvals in the US, Europe and the UK.  

The FDA approval was granted in November 2022 based on the findings from the Phase III HOPE-B trial. The one-off infusion comes with a list price of $3.5m a dose, making it the most expensive drug in the world.  

GlobalData forecasts predict that the global market for haemophilia A and haemophilia B treatments will grow to $14.7bn by 2030, up from $9.4bn in 2020. Gene therapies such as Hemgenix are expected to be significant drivers for this growth.  

GlobalData is the parent company of Pharmaceutical Technology. 

Haemophilia B is a rare, lifelong bleeding disorder caused by a mutation in the F9 gene, resulting in insufficient production of factor IX, a crucial protein needed for proper blood clotting. Hemgenix works by enabling the body to continuously produce factor IX, employing adeno-associated virus (AAV) technology to introduce the Padua gene variant of Factor IX (FIX-Padua) into liver cells promoting the production of factor IX proteins that are significantly more active than normal.  

Traditional treatments for haemophilia B prophylaxis therapy, require strict, lifelong infusion schedules and may not entirely prevent spontaneous bleeding episodes or the associated pain, joint damage, and swelling.  

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

The Phase III HOPE-B trial (NCT03569891), which drove the authorisation, evaluated the safety and efficacy of AMT-061 in patients with severe to moderately severe haemophilia B. The study enrolled 54 subjects, making it the largest gene therapy trial for haemophilia B to date.  

Positive data from the study showed that 94% of patients discontinued prophylactic treatments and remained free of continuous routine prophylaxis therapy after 24 months. 

CSL research and development head Bill Mezzanotte said: “We believe Hemgenix has the potential to change the treatment paradigm for people living with haemophilia B and the healthcare professionals who treat them, as it addresses the cause of the condition – faulty factor IX gene expression.” 

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by CytivaEditorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.